Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLWAVE-002: Nemtabrutinib in Japanese Participants With Hematological Malignancies
NCT05673460Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nemtabrutinib in mature B-cell neoplasm (MBCN), sponsored by Merck & Co. Primary endpoints: Dose Limiting Toxicities at 4 weeks, Adverse Events at 26 months and 1 more. Started Feb 2023; status: completed.
02
Drugs
nemtabrutinib
03
Conditions
mature B-cell neoplasm (MBCN)
Beyond the preview
Go deeper on NCT05673460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673460.